Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDXS logo CDXS
Upturn stock ratingUpturn stock rating
CDXS logo

Codexis Inc (CDXS)

Upturn stock ratingUpturn stock rating
$2.44
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CDXS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $7.08

1 Year Target Price $7.08

Analysts Price Target For last 52 week
$7.08Target price
Low$1.9
Current$2.44
high$6.08

Analysis of Past Performance

Type Stock
Historic Profit -25.56%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 198.00M USD
Price to earnings Ratio -
1Y Target Price 7.08
Price to earnings Ratio -
1Y Target Price 7.08
Volume (30-day avg) 7
Beta 2.53
52 Weeks Range 1.90 - 6.08
Updated Date 06/30/2025
52 Weeks Range 1.90 - 6.08
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.98

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-06-11
When After Market
Estimate -0.18
Actual -0.25

Profitability

Profit Margin -149.47%
Operating Margin (TTM) -271.59%

Management Effectiveness

Return on Assets (TTM) -30.06%
Return on Equity (TTM) -115.53%

Valuation

Trailing PE -
Forward PE 138.89
Enterprise Value 196886740
Price to Sales(TTM) 3.97
Enterprise Value 196886740
Price to Sales(TTM) 3.97
Enterprise Value to Revenue 3.95
Enterprise Value to EBITDA -10.67
Shares Outstanding 82844800
Shares Floating 60458514
Shares Outstanding 82844800
Shares Floating 60458514
Percent Insiders 2.49
Percent Institutions 84.28

Analyst Ratings

Rating 3
Target Price 7.08
Buy 1
Strong Buy 4
Buy 1
Strong Buy 4
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Codexis Inc

stock logo

Company Overview

overview logo History and Background

Codexis Inc. was founded in 2002. It evolved from Maxygen, focusing on protein engineering for pharmaceutical and industrial applications. Key milestones include developing CodeEvolveru00ae technology and strategic partnerships with major companies.

business area logo Core Business Areas

  • Codexis Enzymes: Development and sale of high-performance enzymes for pharmaceutical manufacturing, food, and other industries.
  • CodeEvolveru00ae Platform: Licensing of the CodeEvolveru00ae protein engineering platform to partners for their internal enzyme development programs.

leadership logo Leadership and Structure

The leadership team includes the CEO, CFO, and other executives. The organizational structure comprises R&D, manufacturing, commercial, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • Enzymes for Pharmaceutical Manufacturing: Enzymes used in the synthesis of active pharmaceutical ingredients (APIs). Codexis faces competition from companies like BASF and DSM in the enzyme supply market. While exact market share is difficult to ascertain, Codexis is a significant player in specific enzyme applications. Revenue generated is not publicly broken down, and data on number of users is difficult to collect.
  • Enzymes for Food Industry: Enzymes used in the manufacturing of food products such as human milk oligosaccharides (HMOs). Competitors include Novozymes and DuPont. While exact market share is difficult to ascertain, Codexis is a significant player in specific enzyme applications. Revenue generated is not publicly broken down, and data on number of users is difficult to collect.

Market Dynamics

industry overview logo Industry Overview

The enzyme market is driven by increasing demand for sustainable and efficient manufacturing processes. Growth is fueled by the pharmaceutical, food, and industrial sectors.

Positioning

Codexis is positioned as a leader in enzyme engineering, offering tailored solutions through its CodeEvolveru00ae platform. Its competitive advantages include its technology, expertise, and partnerships.

Total Addressable Market (TAM)

The global industrial enzymes market is estimated to reach billions of dollars. Codexis is well-positioned to capture a significant portion of the TAM through its innovative technology and partnerships.

Upturn SWOT Analysis

Strengths

  • Proprietary CodeEvolveru00ae technology
  • Strong partnerships with leading companies
  • Expertise in enzyme engineering
  • Customizable enzyme solutions

Weaknesses

  • Reliance on partnerships for revenue
  • Limited in-house manufacturing capacity
  • Competition from larger enzyme suppliers

Opportunities

  • Expanding into new enzyme applications
  • Increasing demand for sustainable manufacturing
  • Growth in the biopharmaceutical sector
  • Development of novel enzyme products

Threats

  • Competition from established enzyme suppliers
  • Technological advancements by competitors
  • Economic downturns affecting customer demand
  • Regulatory changes

Competitors and Market Share

competitor logo Key Competitors

  • Novozymes (NVZMY)
  • DSM (RDSMY)
  • BASF (BASFY)

Competitive Landscape

Codexis has a competitive advantage in enzyme engineering but faces competition from larger, established enzyme suppliers.

Growth Trajectory and Initiatives

Historical Growth: Codexis has demonstrated revenue growth over the past several years, driven by partnerships and enzyme sales.

Future Projections: Analysts project continued revenue growth and improved profitability, driven by new enzyme applications and partnerships.

Recent Initiatives: Recent initiatives include expanding partnerships, developing new enzyme products, and investing in manufacturing capacity.

Summary

Codexis is a growing company with a strong technology platform and strategic partnerships. Its reliance on partnerships and competition are challenges. The enzyme market offers significant growth potential. Future performance depends on execution and innovation.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market data and financial information are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Codexis Inc

Exchange NASDAQ
Headquaters Redwood City, CA, United States
IPO Launch date 2010-04-22
President, CEO & Chairman Dr. Stephen George Dilly MBBS, Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 188
Full time employees 188

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.